Trials By City
Reno Nevada Clinical Trials
Listings Sponsored By:
This study is designed to compare the post injection inflammation and pain seen after intravitreal injections of Ranibizumab vs Aflibercept.
Status: Recruiting Start Date: September 2013 Completion Date: October 2014
- 280 patients suffering from active rheumatoid arthritis who have an inadequate response to methotrexate will be evaluated for improvement of disease activity (efficacy) when taking GLPG0634 as monotherapy (3 different doses - [more...] 50mg, 100mg and 200mg once daily) or matching placebo for 24 weeks. - During the course of the study, patients will also be examined for any side effects that may occur (safety and tolerability), and the amount of GLPG0634 present in the blood (Pharmacokinetics) as well as the effects of GLPG0634 on disease- and mechanism of action-related parameters in the blood (Pharmacodynamics) will be determined. Also, the effects of different doses of GLPG0634 administration on subjects' disability, fatigue and quality of life will be evaluated.
Status: Recruiting Start Date: July 2013 Completion Date: January 2015
The purpose of this proof-of-concept study is to determine whether gevokizumab is effective in the treatment of inflammatory erosive osteoarthritis of the hand.
Status: Recruiting Start Date: May 2013 Completion Date: April 2014
This study is being conducted to evaluate the effects of Atrasentan on Renal Outcomes in Subjects with Type 2 Diabetes and Nephropathy.
Status: Recruiting Start Date: May 2013 Completion Date: March 2017
The purpose of this study is to provide patients who have relapsed or refractory Mantle Cell Lymphoma (MCL) with early access to an investigational medication called ibrutinib (PCI-32765) and to collect safety information about the drug.
Status: Recruiting Start Date: April 2013 Completion Date: May 2014
This small study is to investigate the efficacy of Acthar in the treatment of chronic migraine in patients who have failed multiple treatments, including Botox (which is defined as having <30% reduction from baseline in the number of headache days per month). Despite [more...] the widespread use of anti-seizure medications, there remain a significant number of patient whose migraines are refractory to these agents. The pathophysiology of migraine is such that the neural substances calcitonin G related protein (CGRP), substance P, and neurokinin A are released at the trigeminal nerve endings innervating the large cranial and dura mater blood vessels and this neurotrasmission generates migraine associated pain. Because of this, treatment for migraine can be directed towards down regulating those receptor sites accordingly. Acthar may provide pain relief through this mechanist, as ACTH has been shown to inhibit the release of CGRP and may also provide relief through a negative feedback loop as exogenous ACTH inhibits CRH release and mast cell degranulation.
Status: Recruiting Start Date: April 2013 Completion Date:
A study to evaluate the efficacy of SRM003 treatment versus participating sites' standard practice treatment in extending the duration of primary patency after arteriovenous graft surgery in subjects with end-stage renal disease. It is hypothesized that when placed outside [more...] the blood vessel, the seeded SRM003 gelatin matrix containing endothelial cells can provide a continuous supply of multiple growth regulatory compounds to the underlying cells within the blood vessel, while being protected from the effects of blood flow in the vessel(s) or complications resulting from being in direct contact with the point of injury.
Status: Recruiting Start Date: March 2013 Completion Date: August 2015
This study is designed to assess the efficacy and safety of AMG 416 compared with placebo in the treatment of SHPT in CKD subjects receiving hemodialysis as assessed by the change from baseline in serum iPTH, cCa x P and phosphorus.
Status: Recruiting Start Date: March 2013 Completion Date: May 2014
This study will assess the efficacy, safety and tolerability of indacaterol maleate/glycopyrronium bromide in patients with moderate to severe airflow limitation.
Status: Recruiting Start Date: July 2012 Completion Date: March 2014
This study will provide efficacy and safety data of the secukinumab PFS for subcutaneous self-administration in patients with active rheumatoid arthritis who are intolerant to or have had an inadequate response to anti-TNF-α agents.
Status: Recruiting Start Date: October 2012 Completion Date: January 2020
A randomized, placebo-controlled, double-blind, parallel group, multi-center study to assess the safety and efficacy of tiotropium bromide (18 µg) delivered via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD) subjects recovering from hospitalization for an acute exacerbation (Hospital Discharge [more...] Study 2)
Status: Recruiting Start Date: August 2012 Completion Date: February 2015
A 12 month study where 1000 patients with relapsing remitting MS will be randomized 1:1 to fingolimod or approved disease modifying therapy. Patients will be in early stages of the disease and be treatment naive or have only been treated with one class [more...] of DMT (Interferon beta preparation or glatiramer acetate) for no more than 5 years total exposure. Patients will be able to switch to different treatment for safety, efficacy, tolerability or convenience during the study. Primary objective is to evaluate efficacy of fingolimod by assessing patients retention on treatment. Secondary objectives are to compare reasons for discontinuation, adverse events, cognitive impairment, medication satisfaction and change in brain volume measured by MRI.
Status: Recruiting Start Date: June 2012 Completion Date: January 2015
The primary objective of this study is to demonstrate any changes in assessments of pain for patients receiving Synvisc-One compared to control.
Status: Recruiting Start Date: September 2012 Completion Date: March 2015
This multi-center, prospective, observational cohort study will evaluate the effectiveness, safety and utilization of treatments in patients with advanced basal cell carcinoma and basal cell carcinoma nevus syndrome. The total study duration is anticipated to be a maximum of [more...] 8 years, including 3 years for patient recruitment and 5 years follow-up.
Status: Recruiting Start Date: June 2012 Completion Date: September 2020
The purpose of this study is to evaluate whether extended prophylaxis with oral betrixaban can prevent blood clots in the leg and lung that sometime occur in patients hospitalized for an acute medical illness and to compare these results with standard of care enoxaparin. [more...] The safety of betrixaban will also be studied.
Status: Recruiting Start Date: March 2012 Completion Date: September 2015
This study will evaluate the effectiveness and safety of repeat treatment with rifaximin 550 mg three times a day in patients with IBS with diarrhea who respond to initial treatment of rifaximin 550 mg three times a day.
Status: Recruiting Start Date: February 2012 Completion Date:
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy [more...] x-rays to kill tumor cells. It is not yet known whether chemotherapy alone is more effective then chemotherapy plus radiation therapy in treating rectal cancer. PURPOSE: This randomized phase II/III trial studies how well chemotherapy alone compared to chemotherapy plus radiation therapy works in treating patients with rectal cancer undergoing surgery.
Status: Recruiting Start Date: January 2012 Completion Date:
This study is conducted to evaluate the short (12 Weeks) and long term (104 Weeks) efficacy of Certolizumab Pegol compared with Adalimumab both in combination with Methotrexate (MTX) in the treatment of moderate to severe Rheumatoid Arthritis (RA) that is not responding [more...] adequately to MTX.
Status: Recruiting Start Date: December 2011 Completion Date: March 2016
The purpose of this research study is to test two medicines for migraine prevention in children and adolescents. The investigators want to see if amitriptyline and/or topiramate are better than placebo (sugar pill) in reducing headache frequency in children and [more...] adolescents ages 8 to 17 with migraines. At this time, there are no FDA approved medicines approved in the US for the prevention treatment of migraine headaches in children and adolescents.
Status: Recruiting Start Date: June 2012 Completion Date: December 2016
The Biorepository for Caris Life Sciences is designed for the purpose of making quality biospecimens and associated clinical data available for research studies related to advancing precision medicine and improving care for patients. The Caris Biorepository is a repository [more...] of prospectively collected biological specimens and associated clinical and demographic data gathered from multiple sources to be stored, used and shared for research. Caris Life Sciences will maintain the data and specimens and will control access to and use of the information and specimens by multiple individuals for multiple purposes which may evolve over time.
Status: Recruiting Start Date: November 2010 Completion Date: November 2025
This multicenter, randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety carboplatin/paclitaxel and carboplatin/paclitaxel/bevacizumab with and without GDC-0941 in patients with previously untreated advanced or recurrent non-small cell lung cancer (NSCLC). Patients will be randomized to receive 4 [more...] cycles of carboplatin/paclitaxel and either GDC-0941 or placebo, with (patients with non-squamous NSCLC) or without (patients with squamous NSCLC) bevacizumab. Anticipated time on study treatment is until disease progression or intolerable toxicity occurs. Patients in placebo arms with disease progression may cross over to open-label active GDC-0941.
Status: Recruiting Start Date: January 2012 Completion Date: April 2015
In this part of the Registry Program patients with non-valvular atrial fibrillation (AF) at risk for stroke are enrolled to characterize the target population and to collect real world data on important outcome events. For administrative purposes the study is divided into two [more...] protocol numbers: 1160.129 for all non-EU (European Union) and non-EEA (European Economic Area) countries, and 1160.136 for EU and EEA countries. The total number of patients enrolled in both protocols is estimated to be 48,000 patients, and all these patients will be included in the data analysis for study 1160.129.
Status: Recruiting Start Date: November 2011 Completion Date: January 2020
This randomized, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of onartuzumab (MetMAb) in combination with Tarceva (erlotinib) in patients with incurable non-small cell lung cancer identified to be Met diagnostic-positive. Patients will be randomized to receive [more...] either onartuzumab (MetMAb) or placebo in combination with Tarceva. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.
Status: Recruiting Start Date: July 2011 Completion Date: June 2015
Clinical trials allow volunteers access to medical treatment options before they are available to the general public. Participants often receive the best healthcare available for their condition.
Risks are a reality, however, and may include more frequent doctor visits, health risks (possibly life-threatening), and/or the treatment being ineffective. Trials are federally regulated with strict guidelines to protect participants.
Reno Nevada Clinical Trials Information presented on ClinicalTrialsSearch.org is not intended to be a substitute for qualified medical advice visit or treatment with a real physician. We are not physicians. Always consult with a medical doctor (MD). ClinicalTrialsSearch.org is a website dedicated to listing clinical research studies in human subjects, including those specifically related to Reno Nevada. Clinical research trials and medical trials take place in hundreds of cities across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectiveness of new treatments and drugs. The purpose of the studies is to answer specific human health questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions. Clinical trials allow volunteers access to medical treatment options before they are available to the general public. Many times the participants receive treatment for free, and sometimes they are paid for their time. Participants often receive the best healthcare available possible for their condition. Risks are a reality, however, and may include more frequent doctor visits, health risks (possibly life-threatening), and/or the treatment being ineffective. U.S. - based Reno Nevada studies are federally regulated with strict guidelines to protect patients.
There are a number of clinical trials underway to find effective treatments for diabetes, including new drugs, surgery and even transplantation.
There are several current and ongoing trials of interventions for major depressive disorder, which is characterized by a disabling combination of symptoms causing severe disruption to the sufferer's ability to carry out routine functions and tasks of daily life.
Constipation is a illness where the bowels cannot move waste material out of the body in a normal manner. There are various clinical trials recruiting participants to study the effectiveness of various treatments.